Amendments to the Claims/Listing of Claims

Please amend claims 1-3, 19 and 20 and cancel claims 5-11 and 14-18 without prejudice. This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A method for ~~modulating~~ **inhibiting or reducing** growth of ~~neoplastic~~ **myelogenous leukemia** cells, wherein said growth is mediated by peroxisome proliferator activated receptor-γ (PPAR-γ), said method comprising contacting said cells with a composition effective to ~~modulate~~ **inhibit or reduce** said growth,

wherein said composition comprises:

at least one PPAR-γ-**selective** activator, and

at least one retinoid X receptor (RXR) selective agonist,

in a pharmaceutically acceptable carrier therefore,

wherein said PPAR-γ-selective activator is a PPAR-γ-selective prostaglandin; and wherein said retinoid X receptor (RXR) selective agonist is a substituted benzoic acid, a substituted nicotinic acid or a substituted carboxylated furan.

2. (Currently amended) A method according to claim 1 wherein said ~~PPAR-γ activator is a~~ PPAR-γ-selective prostaglandin **has structure II as follows:** ~~or prostaglandin-like compound or precursor thereof~~



wherein:

A is selected from hydrogen or a leaving group at the α- or β- position of the ring, or A is absent when there is a double bond between C^{α} and C^{β} of the ring;

X is an alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl or substituted alkynyl group having in the range of 2 up to 15 carbon atoms; and

Q is an alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl or substituted alkynyl group having in the range of 2 up to 15 carbon atoms.

3. (Currently amended) A method according to claim 2 wherein said PPAR-γ-selective prostaglandin is a prostaglandin-J_2, or a prostaglandin-D_2~~, or a precursor thereof~~.

4. (Original) A method according to claim 3 wherein said prostaglandin-J_2 is prostaglandin-J_2, ^{12}-prostaglandin-J_2 or 15-deoxy-^{12,14}-prostaglandin-J_2.

5-11. (Cancelled)

12. (Original) A method according to claim 1 wherein said retinoid X receptor (RXR) selective agonist is 6-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl]nicotinic acid (LG268).

13. (Original) A method according to claim 1 wherein said retinoid X receptor (RXR) selective agonist is 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid.

14-18. (Cancelled)

19. (Currently amended) A method for treating a subject suffering from ~~a disease state~~ **myelogenous leukemia** which is the result of neoplastic cell proliferation of **myelogenous leukemia** cells which express PPAR-γ, said method comprising administering to said subject an amount of a therapeutic composition effective to ameliorate the effect of neoplastic cell proliferation on said cells,

wherein said therapeutic composition comprises:

at least one PPAR-γ-**selective** activator, and

at least one retinoid X receptor (RXR) selective agonist,

in a pharmaceutically acceptable carrier therefore;

wherein said PPAR-γ-selective activator is a PPAR-γ-selective prostaglandin; and

wherein said retinoid X receptor (RXR) selective agonist is a substituted benzoic acid, a substituted nicotinic acid or a substituted carboxylated furan.

20. (Currently amended) A composition comprising at least one PPAR-γ-selective activator and at least one retinoid X receptor (RXR) selective agonist;

wherein said PPAR-γ-selective activator is a PPAR-γ-selective prostaglandin; and

wherein said retinoid X receptor (RXR) selective agonist is a substituted benzoic, a substituted nicotinic acid or a substituted carboxylated furan.